Members of the Oncologic Drugs Advisory Committee were admittedly conflicted over the benefit-risk profile of Merck & Co. Inc.'s Keytruda in a high-risk bladder cancer, but still gave a positive recommendation on 17 December in part to help drug development in the disease.
Keytruda is proposed for treatment of adults with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma-in-situ (CIS)...





